39325-01-4

39325-01-4 structure

Name: Picibanil
Chemical Name: (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
CAS Number: 39325-01-4
Molecular Formula: C₁₆H₁₇N₂O₄S
Molecular Weight: 333.383
Catalog: Research Areas Cancer
Create Date: 2018-06-03 15:19:53
Modify Date: 2025-08-27 21:34:31
Picibanil (OK-432) is a streptococcal preparation with potent biological response modifying activities. Picibanil also has anticancer activity. Picibanil can be used for the research of cancers such as lymphangiomas[1][2][3].

Name	(2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
Synonyms	(2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-, ion(1-), (2S,5R,6R)-

Description	Picibanil (OK-432) is a streptococcal preparation with potent biological response modifying activities. Picibanil also has anticancer activity. Picibanil can be used for the research of cancers such as lymphangiomas[1][2][3].
Related Catalog	Research Areas >> Cancer Research Areas >> Infection Signaling Pathways >> Others >> Others Research Areas >> Inflammation/Immunology
In Vitro	OK-432 诱导多种细胞因子，激活免疫细胞，增强抗癌免疫力[3]。 OK-432 诱导树突状细胞 (DC) 成熟[3]。
In Vivo	Picibanil（腹腔注射；1.0 KE/小鼠；2-10 天）增加白细胞介素 1 (IL-1) 和白细胞介素 2 (IL-2) 的产生[2]。 Animal Model: BALB/c mice[2] Dosage: 1.0 KE/mouse Administration: Intraperitoneal; 2-10 day Result: Augmented IL-I production by macrophages and 1L-2 production.
References	[1]. Ryoma, Yoshiki et al. Biological effect of OK-432 (picibanil) and possible application to dendritic cell therapy. Anticancer research vol. 24,5C (2004): 3295-301. [2]. Ichimura, O et al. Augmentation of interleukin 1 and interleukin 2 production by OK-432. International journal of immunopharmacology vol. 7,2 (1985): 263-70. [3]. Giguère, Chantal M et al. Treatment of lymphangiomas with OK-432 (Picibanil) sclerotherapy: a prospective multi-institutional trial. Archives of otolaryngology--head & neck surgery vol. 128,10 (2002): 1137-44.